Risk of Hyponatremia Induced by a Selective Serotonin Reuptake Inhibitor: A Case Report

選擇性血清素再回收抑制劑治療引起的低鈉血症的風險：個案報告

林聖祐(Sheng-Yu Lin)；高霈馨(Pei-Hsin Kao)；張鳳麟(Fong-Lin Jang)

台灣精神醫學

32卷3期（2018 / 09 / 01）

239 - 241

英文

1. De Picker, L,Van Den Eede, F,Dumont, G,Moorkens, G,Sabbe, BG(2014).Antidepressants and the risk of hyponatremia: a class-by-class review of literature.Psychosomatics,55,536-547.
2. Jacob, S,Spinler, SA(2006).Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults.Ann Pharmacother,40,1618-1622.
3. Leth-Moller, KB,Hansen, AH,Torstensson, M(2016).Antidepressants and the risk of hyponatremia: a Danish register-based population study.BMJ Open,6,e011200.
4. Mogi, T,Yoshino, A,Ikemoto, G,Nomura, S(2012).Mirtazapine as an alternative for selective-serotonin-reuptake-inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone.Psychiatry Clin Neurosci,66,80.
5. Naranjo, CA,Busto, U,Sellers, EM(1981).A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther,30,239-245.
6. Stahl, SM(2014).Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties.CNS Spectr,19,207-212.
7. Varela Pinon, M,Adan-Manes, J(2017).Selective serotonin reuptake inhibitor-induced hyponatremia: clinical implications and therapeutic alternatives.Clin Neuropharmacol,40,177-179.